Immune Therapeutics, Inc.

Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease. Immune Therapeutics is actively developing T-cell activation immunotherapies in combination with other drug candidates to achieve immunomodulation in patients with cancer, auto-immune disease and inflammatory diseases

Recent News

  • Immune Therapeutics, Inc. Appoints New Independent Director

    Fort Collins, Colorado--(Newsfile Corp. - February 18, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases that has announced the appointment of Mr. Michael L. Sander to ...

    2020-02-18 11:52 AM ET
  • Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

    Orlando, Florida--(Newsfile Corp. - February 11, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse ...

    2020-02-11 9:00 AM ET